Triplet Therapy Determination Phase 3 Trial | Paul Richardson, MD | ASH 2023

Modern DLBCL Treatments: Smart Stop Trial | Jason Westin, MD | ASH 2023

Assessing Lenalidomide with Patients Progressing on JAK Inhibitors | James Berenson, MD | ASH 2023

Circulating Tumor DNA as a Detection Tool Following DLBCL Therapy | Mark Roschewski, MD | ASH 2023

BCMA and GPRC5D Targeted Therapy | Luciano Costa, MD, PhD | ASH 2023

ALPINE Trial: Zanubrutinib vs Ibrutinib in Treating CLL | Constantine Tam, MD, MBBS | ASH 2023

Applying the EHA/EBMT Grading System for Icaht Following CAR-T Therapy | Kai Rejeski, MD | ASH 2023

Richter's Transformation & CAR T Therapy in CLL | Adam Kittai, MD | ASH 2023

Results from the Optimum/Muknine Trial | Martin Kaiser, MD, FRCP, FRCPath | ASH 2023

Effects of Dose Reductions of Lenalidomide in Myeloma Patients | Jens Hillengass, MD, PhD | ASH 2023

PD-1 Blockade Pre-Transplant Improves Outcomes in Hodgkin Lymphoma

Treatment Locations for Young Adults with Aggressive B-Cell Lymphomas

Impact of Frailty on Outcomes After CAR T-Cell Therapy | Hamza Hashmi | ASH 2023

Talquetamab + Pomalidomide in Myeloma: MonumenTAL-2 Safety & Efficacy | Jeffrey Matous, MD |ASH 2023

Predicting DDX41-Mutant MDS Outcomes Needs a Risk Scoring System | Carmelo Gurnari | ASH 2023

Non-Relapse Mortality Following CAR-T Therapy | Kai Rejeski, MD | ASH 2023

Real-World Analysis in Refractory Hodgkin Lymphoma Patients